Risk Partners Life Sciences Roundtable 2024, thank you very much! Sign up now for the 26.06.2025 >

Risk Partners on Going Public and the capital market blog on prospectus liability
insurance

Over the past few months, we have expanded our expertise in the Prospectus liability insurance with a broad audience on two renowned platforms. Here is an overview:

  • Kapitalmarkt.blog
    In the article "POSI insurance - the protective vest on the capital market", we explain why prospectus liability insurance is an indispensable tool for companies that are active on the capital market. The article shows in a practical way how such insurance not only minimizes liability risks, but also strengthens investor confidence.

  • GoingPublic Magazine
    In "Liability risks in uplisting and private placements", we focus on the particular risks that arise in private placements and the switch to regulated market segments. Here, too, we emphasize how well thought-out prospectus liability insurance can create the necessary security for issuers.

From our projects and the special features of POSI and D&O insurance as claims-made insurances, we know how important it is to have such an insurance program ideally in place. 24 months in advance structure. It is therefore important for us to share our knowledge and expertise so that companies are optimally prepared for the challenges.

🔍 How can we help you? Whether you are planning an IPO, preparing a private placement or want to protect your company against potential liability risks: We provide you with comprehensive advice on Prospectus liability insurance and develop the optimum solution for your requirements.

👉 Get in touch with us today!

Also read our other blog posts

Management

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research

Research mishap at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it? An incident that threatens your very existence, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences. What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result. The material was stored in deep-freeze tanks in which the temperature

Read more "
Being Public

Digital and effective prevention of directors' and officers' liability by Risk Partners & Fides Technology

Innovation by Risk Partners & Fides Technology Now on Vimeo and Soundcloud: get practical tips from experts with high relevance for avoiding liability for business managers. Question unanswered? Content: Personal liability is a constant sword of Damocles hovering over managing directors in everyday life. The standard of care is strict and directors bear the burden of proof. In collaboration with the distinguished corporate lawyer Eva Homborg (Esche Schümann Commichau) and the governance expert Philippa Peters (Fides Technology GmbH), we have spent months compiling practical measures on how you can avoid this burden of proof.

Read more "
Risk Partners

13th Hamburg Financial Lines Forum

Risk Partners at the Financial Lines Forum 13th Hamburg Financial Lines Forum. On October 12 and 13, 2023, the 13th Hamburg Financial Lines Forum took place with the participation of Risk Partners, a traditional event that once again served as a platform for the exchange of current trends. The program began with an overview of current developments and the handling of claims in financial lines, presented by Gabriele Schreiber-Sahin and Michael Hendricks. Dr. Oliver Sieg then shed light on directors' and officers' liability and the

Read more "
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
Being Public

Risk Partners supports successful IPO of Steyr Motors AG

We congratulate Steyr Motors AG on its successful listing in the Scale Segment of the German Stock Exchange on October 30, 2024! Risk Partners had the honor to act as IPO underwriting advisor on this transaction. Our team, led by Florian Eckstein and Björn Stressenreuter, supported Steyr Motors AG in its IPO on the Frankfurt Stock Exchange. Our expertise and comprehensive support were focused on providing Steyr Motors with a safe and successful start on the capital markets. We would like to thank Julian Cassutti and Christoph Cerar from Steyr Motors

Read more "
Being Public

Revolution in D&O insurance in Nevada (US insurance market) postponed

The revolution in D&O insurance in Nevada has been called off after all. In the US market, the state of Nevada passed an interesting law (Bill No. 398) in the summer with potentially significant implications for the D&O insurance market. The Governor of Nevada approved the bill on June 3, 2023, so the law came into force on October 1, 2023. We had classified this legislation (in the USA, insurance supervision is organized at state level) as too watchful for our clients, but this law

Read more "